Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2021.721830
Abstract: The prognosis of malignant gliomas remains poor, with median survival fewer than 20 months and a 5-year survival rate merely 5%. Their primary location in the central nervous system (CNS) and its immunosuppressive environment with… read more here.
Keywords: gliomas; immunotherapy; malignant gliomas; treatment ... See more keywords
Immunogenic cell death: The cornerstone of oncolytic viro-immunotherapy
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.1038226
Abstract: According to the World Health Organization, cancer is one of the leading global health concerns, causing nearly 10 million deaths in 2020. While classical chemotherapeutics produce strong cytotoxicity on cancer cells, they carry limitations of… read more here.
Keywords: cell death; cancer; immunogenic cell; oncolytic viro ... See more keywords
Optimising Hydrogel Release Profiles for Viro-Immunotherapy Using Oncolytic Adenovirus Expressing IL-12 and GM-CSF with Immature Dendritic Cells
Sign Up to like & getrecommendations! Published in 2020 at "Applied Sciences"
DOI: 10.3390/app10082872
Abstract: Sustained-release delivery systems, such as hydrogels, significantly improve cancer therapies by extending the treatment efficacy and avoiding excess wash-out. Combined virotherapy and immunotherapy (viro-immunotherapy) is naturally improved by these sustained-release systems, as it relies on… read more here.
Keywords: immunotherapy; release profiles; viro immunotherapy; immature dendritic ... See more keywords